Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In 3D Systems To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in 3D System between August 13, 2024 and May 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, July 3, 2025 /PRNewswire/ -- Faruqi & Faruq ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Rocket Pharmaceuticals between February 27, 2025 and May 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, July 3, 2025 /PR ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In PepGen To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in PepGen between March 7, 2024 and March 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, July 3, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, ...

Core Points - Holzer & Holzer, LLC is investigating Quantum Corporation for potential compliance issues with federal securities laws following the company's inability to file its Annual Report on Form 10-K for the fiscal year ended March 31, 2025 [1] - Quantum disclosed that it is reviewing its accounting related to certain revenue contracts and the application of standalone selling price under applicable accounting standards, which led to a drop in its stock price [1] Company Information - Quantum Corporation trades on NASDAQ under the ticker QMCO [1] - The company has faced scrutiny due to its accounting practices, which may impact investor confidence and stock performance [1] Legal Context - Holzer & Holzer, LLC is a law firm specializing in securities litigation, representing shareholders and investors in cases of corporate misconduct [3] - The firm has a history of recovering significant amounts for shareholders affected by fraud, indicating a proactive approach to investor rights [3]

NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP , a global investor rights law firm, reminds purchasers of Fortrea Holdings, Inc. (NASDAQ: FTRE) (“Fortrea”) securities between July 3, 2023 and February 28, 2025 (the “Class Period”), inclusive, of the important August 1, 2025 deadline to seek appointment as lead plaintiff in the securities class action lawsuit. Investors who purchased or otherwise acquired shares of Rocket should contact the Firm prior to the August 1, 2 ...

ATLANTA, June 26, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Civitas Resources, Inc. (“Civitas” or the “Company”) (NYSE: CIVI). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information regarding Civitas’s business, operations, and prospects, including allegations that: (i) Civitas was highly likely to significantly reduce its oil production in 2025 as a result of, among other things, ...

ATLANTA, June 26, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) complied with federal securities laws. On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH), revealing that the trial did not demonstrate statistical significance for the endpoint of improving fibrosis while not worsening MASH. Following this news, the pri ...

Core Insights - Holzer & Holzer, LLC is investigating Ichor Holdings, Ltd. for potential compliance issues with federal securities laws following disappointing Q1 2025 financial results [1] - Ichor's CEO indicated that the company's strategy did not yield the expected margin flow due to higher-than-forecasted external supply purchases [1] - The announcement of these results led to a decline in Ichor's stock price [1] Company Overview - Ichor Holdings, Ltd. trades on NASDAQ under the ticker ICHR [1] - The company reported its Q1 2025 financial results on May 5, 2025 [1] Legal Context - Holzer & Holzer, LLC is a law firm specializing in securities litigation, representing shareholders and investors in various legal actions [3] - The firm has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]

ATLANTA, June 25, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Myriad Genetics, Inc. (“Myriad Genetics” or the “Company”) (NASDAQ: MYGN) complied with federal securities laws. On May 6, 2025, Myriad Genetics reported first quarter 2025 financial results, and lowered its 2025 financial guidance, revealing, among other things, a decline in pharmacogenomics revenue by 20% year-over-year “due to UnitedHealthcare (UNH) reduc[ing] coverage of GeneSight.” Following this news, the price of ...

Core Viewpoint - A class action lawsuit has been filed against Compass Group Diversified Holdings LLC due to alleged failures in financial reporting and internal controls, leading to significant stock price decline following the revelation of these issues [3][4][5]. Group 1: Lawsuit Details - The class action lawsuit, Nicholas Moreno v. Compass Group Diversified Holdings LLC, has been amended and is ongoing in the United States District Court for the District of Connecticut [1]. - The lawsuit pertains to securities purchased between February 24, 2022, and May 7, 2025, and claims that Compass failed to disclose critical information regarding its subsidiary, Lugano Holding, Inc. [1][3]. Group 2: Financial Reporting Issues - Compass Group's internal controls over financial reporting were deemed ineffective, and undisclosed financing arrangements related to Lugano were highlighted as problematic [3]. - The company announced on May 7, 2025, that its financial statements for fiscal 2024 could no longer be relied upon due to an internal investigation into Lugano's financing of inventory [4]. Group 3: Stock Price Impact - Following the announcement of the investigation, Compass' stock price plummeted from $17.25 per share on May 7, 2025, to $6.55 per share on May 8, 2025, indicating a dramatic loss in market value [5].